You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer
|
|---|---|
| Published in |
Clinical Epigenetics, April 2018
|
| DOI | 10.1186/s13148-018-0479-y |
| Pubmed ID | |
| Authors |
Lieselot Croes, Matthias Beyens, Erik Fransen, Joe Ibrahim, Wim Vanden Berghe, Arvid Suls, Marc Peeters, Patrick Pauwels, Guy Van Camp, Ken Op de Beeck |
| Abstract |
Breast cancer is the most frequent cancer among women worldwide. Biomarkers for early detection and prognosis of these patients are needed. We hypothesized that deafness, autosomal dominant 5 (DFNA5) may be a valuable biomarker, based upon strong indications for its role as tumor suppressor gene and its function in regulated cell death. In this study, we aimed to analyze DFNA5 methylation and expression in the largest breast cancer cohort to date using publicly available data from TCGA, in order to further unravel the role of DFNA5 as detection and/or prognostic marker in breast cancer. We analyzed Infinium HumanMethylation450k data, covering 22 different CpGs in the DFNA5 gene (668 breast adenocarcinomas and 85 normal breast samples) and DFNA5 expression (Agilent 244K Custom Gene Expression: 476 breast adenocarcinomas and 56 normal breast samples; RNA-sequencing: 666 breast adenocarcinomas and 71 normal breast samples). DFNA5 methylation and expression were significantly different between breast cancer and normal breast samples. Overall, breast cancer samples showed higher DFNA5 methylation in the putative gene promoter compared to normal breast samples, whereas in the gene body and upstream of the putative gene promoter, the opposite is true. Furthermore, DFNA5 methylation, in 10 out of 22 CpGs, and expression were significantly higher in lobular compared to ductal breast cancers. An important result of this study was the identification of a combination of one CpG in the gene promoter (CpG07504598) and one CpG in the gene body (CpG12922093) of DFNA5, which was able to discriminate between breast cancer and normal breast samples (AUC = 0.93). This model was externally validated in three independent datasets. Moreover, we showed that estrogen receptor state is associated with DFNA5 methylation and expression. Finally, we were able to find a significant effect of DFNA5 gene body methylation on a 5-year overall survival time. We conclude that DFNA5 methylation shows strong potential as detection and prognostic biomarker for breast cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 13 | 21% |
| Student > Master | 5 | 8% |
| Researcher | 4 | 6% |
| Student > Bachelor | 4 | 6% |
| Student > Ph. D. Student | 4 | 6% |
| Other | 10 | 16% |
| Unknown | 22 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 14 | 23% |
| Unspecified | 13 | 21% |
| Medicine and Dentistry | 3 | 5% |
| Agricultural and Biological Sciences | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 7 | 11% |
| Unknown | 21 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2020.
All research outputs
#3,783,121
of 23,043,346 outputs
Outputs from Clinical Epigenetics
#244
of 1,266 outputs
Outputs of similar age
#75,447
of 329,173 outputs
Outputs of similar age from Clinical Epigenetics
#8
of 31 outputs
Altmetric has tracked 23,043,346 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,266 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,173 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.